Beijing Kawin Technology Share-Holding Co., Ltd. (688687.SS)

CNY 24.11

(0.17%)

Market Cap (In CNY)

4.03 Billion

Revenue (In CNY)

1.41 Billion

Net Income (In CNY)

116.52 Million

Avg. Volume

2.33 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
18.5-35.79
PE
-
EPS
-
Beta Value
1.094
ISIN
CNE1000054C3
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Desheng Zhou
Employee Count
-
Website
https://www.kawin.com.cn
Ipo Date
2021-02-08
Details
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substances–fermentation and purification, drug product–formulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.